“Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial” (2022) SKIN The Journal of Cutaneous Medicine, 6(6), p. s65. doi:10.25251/skin.6.supp.65.